In an open-label, randomized large phase III study known as the ADMIRAL trial, patients with R/R FLT3 mutant AML were randomized in a 2:1 manner to receive gilteritinib monotherapy or salvage chemotherapy. The gene discussed is FLT3; the disease is acute myeloid leukemia.